2025-08-25 - Analysis Report
Okay, here's the report on Merck & Co Inc (MRK), incorporating the data you've provided:

## Merck & Co Inc (MRK) Stock Analysis

**Ticker:** MRK
**Company:** Merck & Co Inc.
**Description:** A global pharmaceutical company that develops and markets a wide range of innovative medicines and vaccines.

### 1. Performance Analysis

*   **Cumulative Return (MRK):** -4.80%
*   **Cumulative Return (VOO):** 38.83%
*   **Return Disparity:**
    *   Current Difference: -107.0%
    *   Range: Max: 23.1, Min: -111.0
    *   Relative Disparity: 3.0 (This indicates that MRK is currently near the bottom of its historical performance range relative to VOO.)

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha    | Beta    | Cap(B) |
|------------|---------|---------|----------|---------|--------|
| 2015-2017  | 5.0%    | 58.2%   | 5.0%     | 1.0     | 134.1  |
| 2016-2018  | 43.0%   | 66.4%   | 43.0%    | 1.0     | 182.1  |
| 2017-2019  | 40.0%   | 66.4%   | 40.0%    | 1.0     | 216.8  |
| 2018-2020  | 20.0%   | 66.4%   | 20.0%    | 1.0     | 195.0  |
| 2019-2021  | -1.0%   | 65.6%   | -2.0%    | 0.0     | 191.4  |
| 2020-2022  | 13.0%   | 69.5%   | 24.0%    | -0.0    | 277.1  |
| 2021-2023  | 31.0%   | 69.5%   | 22.0%    | -0.0    | 272.3  |
| 2022-2024  | -7.0%   | 69.5%   | -37.0%   | -0.0    | 248.5  |
| 2023-2025  | -57.0%  | 71.5%   | -102.0%  | 0.0     | 218.2  |

*   **Analysis:** The table shows a significant decline in performance, particularly in the most recent periods (2022-2025).  Alpha has turned sharply negative, indicating underperformance relative to the benchmark, and Beta is near zero, suggesting the stock's price is not highly correlated with the overall market. CAGR and MDD are also declining while MDD is increasing.

### 2. Recent Stock Price Movement

*   **Current Price:** 87.37
*   **Previous Close:** 86.08
*   **Change:** 1.5
*   **5-Day Moving Average:** 85.45
*   **20-Day Moving Average:** 82.21
*   **60-Day Moving Average:** 81.11

*   **Analysis:** The current price is above all three moving averages, indicating a short-term upward trend.  The recent price increase of 1.5 from the previous close suggests positive momentum.

### 3. Technical Indicators and Signals

*   **Market Risk Indicator (MRI):** 0.3377 (Low Risk)
*   **RSI:** 81.11 (Overbought)
*   **PPO:** 0.7451
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Disparity Change:** 2.9 (+) - Short-term increase
*   **Expected Return (%):** -406.4 (Long-term, relative to S&P 500)

*   **Analysis:** The RSI indicates the stock is currently overbought, which could suggest a potential pullback.  The Hybrid Signal recommends a cautious buy.  The recent increase in relative disparity is positive. The high negative Expected Return is concerning and should be a key area for further investigation.
    *   The positive change in the last market data (`{'price': 87.37, 'previousClose': 86.08, 'change': 1.5}`) does indicate a recent upward movement. While not necessarily a "급반등" (sudden surge), it contributes to the overall positive short-term momentum.

### 4. Recent News & Significant Events

*   **2025-08-22:** Major business developments, regulatory changes, or market events.
*   **2025-08-23:** Analyst discussions regarding recent performance and outlook.
*   **2025-08-25:** Notable stock volatility influenced by recent news, earnings, or executive actions.
*   **2025-08-21:** Experts highlight risks and opportunities; investors advised to monitor news and announcements.

*   **Analysis:** The news suggests that MRK has been subject to recent events impacting the stock performance. Investor sentiment is likely to be volatile, and decisions should be made with careful consideration of risks and opportunities.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-08-05 | 1.76 | 15.81 B$     |
| 2025-05-02 | 2.01 | 15.53 B$     |
| 2024-11-06 | 1.25 | 16.66 B$     |
| 2024-08-05 | 2.15 | 16.11 B$     |
| 2025-08-05 | 2.15 | 16.11 B$     |

*   **Analysis:** EPS and revenue have fluctuated, with the most recent EPS being lower compared to some previous quarters.  This fluctuation may be contributing to the recent stock volatility.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | $15.81B  | 77.50%        |
| 2025-03-31   | $15.53B  | 77.98%        |
| 2024-12-31   | $15.62B  | 75.50%        |
| 2024-09-30   | $16.66B  | 75.51%        |
| 2024-06-30   | $16.11B  | 76.76%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE    |
|--------------|----------|--------|
| 2025-06-30   | $48.99B  | 9.04%  |
| 2025-03-31   | $48.34B  | 10.51% |
| 2024-12-31   | $46.31B  | 8.08%  |
| 2024-09-30   | $44.50B  | 7.09%  |
| 2024-06-30   | $43.58B  | 12.52% |

*   **Analysis:** Revenue has been relatively stable, but profit margins have seen some fluctuation. Equity has generally been increasing, while ROE has fluctuated significantly, which may suggest an increasing equity base is not leading to better returns, impacting investor sentiment.

### 7. Overall Summary

Merck & Co Inc (MRK) is currently exhibiting a mixed picture. While the short-term price movement is positive, its long-term performance relative to the S&P 500 is significantly negative. The recent news suggests volatility, and financial data reveals fluctuating profitability and ROE. The extremely negative Expected Return warrants a deeper investigation into the factors affecting the company's future prospects. While the Market Risk Indicator suggests low risk, the overbought RSI and negative Expected Return indicate caution is warranted. The negative Alpha over recent periods suggests the company is struggling to outperform its benchmark.
